Dopamine and non-dopamine psychoses

David L. Garver, Frank Zemlan, Jack Hirschowitz, Robert Hitzemann, Michael L. Mavroidis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations. Rapid responders (RRs) had 60% reduction of baseline psychotic symptoms by a mean of 5.5 days of drug treatment. Delayed/nonresponders required 2-7 weeks for a similar reduction of psychotic symptoms. The sensitivity of postsynaptic dopamine receptors was explored using a neuroendocrine probe: growth hormone response to the dopamine agonist, apomorphine (AP). RRs had an exaggerated growth hormone response to AP in comparison to delayed/nonresponders (P

Original languageEnglish (US)
Pages (from-to)138-140
Number of pages3
JournalPsychopharmacology
Volume84
Issue number1
DOIs
StatePublished - Sep 1984
Externally publishedYes

Fingerprint

Psychotic Disorders
Antipsychotic Agents
Dopamine
Apomorphine
Dopamine Receptors
Growth Hormone
Dopamine Agonists
Reaction Time
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Antipsychotic drug
  • Apomorphine
  • Cholecystokinin
  • Dopamine
  • Drug response latency
  • Growth hormone
  • Neuroleptic
  • Neuropeptides
  • Receptor sensitivity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Garver, D. L., Zemlan, F., Hirschowitz, J., Hitzemann, R., & Mavroidis, M. L. (1984). Dopamine and non-dopamine psychoses. Psychopharmacology, 84(1), 138-140. https://doi.org/10.1007/BF00432044

Dopamine and non-dopamine psychoses. / Garver, David L.; Zemlan, Frank; Hirschowitz, Jack; Hitzemann, Robert; Mavroidis, Michael L.

In: Psychopharmacology, Vol. 84, No. 1, 09.1984, p. 138-140.

Research output: Contribution to journalArticle

Garver, DL, Zemlan, F, Hirschowitz, J, Hitzemann, R & Mavroidis, ML 1984, 'Dopamine and non-dopamine psychoses', Psychopharmacology, vol. 84, no. 1, pp. 138-140. https://doi.org/10.1007/BF00432044
Garver DL, Zemlan F, Hirschowitz J, Hitzemann R, Mavroidis ML. Dopamine and non-dopamine psychoses. Psychopharmacology. 1984 Sep;84(1):138-140. https://doi.org/10.1007/BF00432044
Garver, David L. ; Zemlan, Frank ; Hirschowitz, Jack ; Hitzemann, Robert ; Mavroidis, Michael L. / Dopamine and non-dopamine psychoses. In: Psychopharmacology. 1984 ; Vol. 84, No. 1. pp. 138-140.
@article{345c50540f77475eae583c6f4510a6f4,
title = "Dopamine and non-dopamine psychoses",
abstract = "The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations. Rapid responders (RRs) had 60{\%} reduction of baseline psychotic symptoms by a mean of 5.5 days of drug treatment. Delayed/nonresponders required 2-7 weeks for a similar reduction of psychotic symptoms. The sensitivity of postsynaptic dopamine receptors was explored using a neuroendocrine probe: growth hormone response to the dopamine agonist, apomorphine (AP). RRs had an exaggerated growth hormone response to AP in comparison to delayed/nonresponders (P",
keywords = "Antipsychotic drug, Apomorphine, Cholecystokinin, Dopamine, Drug response latency, Growth hormone, Neuroleptic, Neuropeptides, Receptor sensitivity",
author = "Garver, {David L.} and Frank Zemlan and Jack Hirschowitz and Robert Hitzemann and Mavroidis, {Michael L.}",
year = "1984",
month = "9",
doi = "10.1007/BF00432044",
language = "English (US)",
volume = "84",
pages = "138--140",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Dopamine and non-dopamine psychoses

AU - Garver, David L.

AU - Zemlan, Frank

AU - Hirschowitz, Jack

AU - Hitzemann, Robert

AU - Mavroidis, Michael L.

PY - 1984/9

Y1 - 1984/9

N2 - The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations. Rapid responders (RRs) had 60% reduction of baseline psychotic symptoms by a mean of 5.5 days of drug treatment. Delayed/nonresponders required 2-7 weeks for a similar reduction of psychotic symptoms. The sensitivity of postsynaptic dopamine receptors was explored using a neuroendocrine probe: growth hormone response to the dopamine agonist, apomorphine (AP). RRs had an exaggerated growth hormone response to AP in comparison to delayed/nonresponders (P

AB - The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations. Rapid responders (RRs) had 60% reduction of baseline psychotic symptoms by a mean of 5.5 days of drug treatment. Delayed/nonresponders required 2-7 weeks for a similar reduction of psychotic symptoms. The sensitivity of postsynaptic dopamine receptors was explored using a neuroendocrine probe: growth hormone response to the dopamine agonist, apomorphine (AP). RRs had an exaggerated growth hormone response to AP in comparison to delayed/nonresponders (P

KW - Antipsychotic drug

KW - Apomorphine

KW - Cholecystokinin

KW - Dopamine

KW - Drug response latency

KW - Growth hormone

KW - Neuroleptic

KW - Neuropeptides

KW - Receptor sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0021209689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021209689&partnerID=8YFLogxK

U2 - 10.1007/BF00432044

DO - 10.1007/BF00432044

M3 - Article

C2 - 6149592

AN - SCOPUS:0021209689

VL - 84

SP - 138

EP - 140

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -